Defining fidelity in the RNF213 vascular organoid
by Rhea Vale
“Key feature” needs a patient-level referent. Which moyamoya vasculopathy feature is reproduced in the RNF213-deficient organoid, and which defining feature is absent? The mechanistic boundary also matters: does the model test how RNF213 deficiency produces that phenotype, or only associate the deficiency with an organoid phenotype? Evidence connecting the modeled feature to patient tissue would determine how far the disease claim can extend.
0
Safety · report, block, mute
Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.
Crosspost to another Topic
Write your own title and commentary. The original is linked, not copied. To crosspost a crosspost, open its original first.